Alternative in vitro models used in the main safety tests of cosmetic products and new challenges

Edith Filaire1,2 | Rachida Nachat-Kappes3 | Camille Laporte4 | Marie-Françoise Harmand1 | Marina Simon1 | Christian Poinsot1

1 Groupe ICARE, Saint Beauzire, France
2 UMR 1019 INRAE-University Clermont-Auvergne, UNH (Human Nutrition Unity), ECREIN Team, Clermont-Ferrand, France
3 InnovSkin, Chatel-Guyon, France
4 Univ. Grenoble Alpes, CEA-Leti: Biology Division, Grenoble, France

Abstract
Background: Guided by ethical considerations and regulatory requirements such as the 7th Amendment to the European Cosmetics Directive N° 1223/2009, the cosmetic industry has developed and evaluated alternative test strategies such as in vitro assays, in silico approaches for toxicological endpoints and efficacy of cosmetic products and cosmetics ingredients. In consequence, the European Centre for the Validation of Alternative Methods (ECVAM) has proposed a list of validated cell-based in vitro models for predicting the safety and toxicity of cosmetic ingredients. These models have been demonstrated as valuable and effective tools to overcome the limitations of animal in vivo studies. For example, 3D human skin equivalent models are used to evaluate skin irritation potential; and excised human skin is used as the gold standard for the evaluation of dermal absorption.

Objective: This review presents, in relation to the regulatory requirements, the main alternative in vitro models used in the safety tests of cosmetic products, focusing on skin sensitization, skin corrosion, skin irritation and skin absorption, with advantages and limitations of each model. Recent innovative 3D cell technologies such as Organ-on-a-Chip (OoC) models that can bring significant improvements for toxicology and efficacy testing are also presented.


Conclusion: The development of OoC technology is promising for assessing the toxicity of substances contained in cosmetics, particularly for repeated dose toxicity, for which no alternative in vitro methods are currently available.
Nevertheless, aside from the challenges, the technology needs to be validated and accepted by regulatory organizations as an effective method. Collaboration between researchers, regulatory organizations and industry would be required to achieve this validation.

Correspondence
Edith Filaire, Groupe ICARE, Biopôle, Rue Emile Duclaux 63360 Saint Beauzire/UMR 1019 INRAE-University Clermont-Auvergne, UNH ECREIN Team, 63000 Clermont-Ferrand, France.
Email: edithfilaire@gmail.com

Download the article